Refixia IV 500, manufactured by Novo Nordisk Pharma, contains nonacog beta pegol (genetical recombination), a recombinant human factor IX with a PEG conjugate used for the treatment and prophylaxis of bleeding in hemophilia B patients 12 years and older. It has a YJ code of 6343452D1026 and a standard of 500 IU 1 bottle (with dissolving solution).
Refixia IV 500
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →